The use of glucagon-like peptide-1 (GLP-1)-based therapies, including GLP-1 receptor agonists (RAs) and tirzepatide, is increasing, based on their benefits for cardiovascular and renal health, in addition to their well-established capacity to improve glycemic control in individuals with type 2 diabetes (T2D) (1, 2) and induce weight loss (3). Here, GLP1R is linked to type 2 diabetes mellitus.